PCSK9 and Other metabolic disease: As proof, subcutaneous injection of the PCSK9 inhibitor SBC-115076 had greater benefit than the cholesterol-reducing drug atorvastatin in improving metabolic disorders of obese rats, because, according to the authors, it could decrease PCSK9 activity in the intestine and cholesterol absorption.